Finance

Lists
RCEL:NASDAQ
AVITA Medical Inc
11,73 $
-1,92%
(-0,23) 1D
11,73 $
0,00% (0,00)
After hours
Closed: 30 սեպ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCEL...
Open
11,90 $
High
12,12 $
Low
11,60 $
Mkt. cap
362,77 մլն
Avg. vol.
350,65 հզր
Volume
0,00
52-wk high
12,23 $
52-wk low
3,22 $
EPS
-1,44 $
Beta
2,02
Shares outstanding
30,93 մլն
No. of employees
226
Open
11,90 $
High
12,12 $
Low
11,60 $
Mkt. cap
362,77 մլն
Avg. vol.
350,65 հզր
Volume
0,00
52-wk high
12,23 $
52-wk low
3,22 $
EPS
-1,44 $
Beta
2,02
Shares outstanding
30,93 մլն
No. of employees
226
News stories
From web sources and news partners
Profile
Avita Medical is a clinical and commercial company developing and marketing a range of regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are PermeaDerm, a transparent, biosynthetic bilayer wound matrix used for temporary wound coverage after surgical excision of burns or trauma, and Cohealyx, a bovine-derived collagen dermal matrix used by burn and trauma surgeons to treat severe wounds and full-thickness burns by accelerating blood vessel formation in order to prepare damaged wound beds for skin autografts. Wikipedia
About AVITA Medical Inc
CEOJames Corbett
Employees226
Founded1999
HeadquartersValencia, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Analyst ratings
Based on 3 analysts giving stock ratings to RCEL in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for RCEL in the last 3 months.
Highest
Current 11,73 $
14,00 $ (+19,35%)
Average
12,33 $ (+5,12%)
Lowest
11,00 $ (-6,22%)
Analyst
Recommendation
Action
Price target
Projected
Date
Josh Jennings
TD Cowen
Buy
Maintained
14,00 $
+19,4%
09/17/2026
Frank Takkinen
Lake Street
Buy
Reiterated
12,00 $
+2,3%
08/28/2026
Ryan Zimmerman
BTIG
Buy
Maintained
11,00 $
-6,2%
08/19/2026
Chad Messer
Lake Street
Buy
Reiterated
6,00 $
-48,8%
07/16/2026
Carl Byrnes
Northland Securities
Buy
Maintained
10,00 $
-14,7%
03/26/2026
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
17,06 մլն
17,62 մլն
19,25 մլն
21,70 մլն
Cost of goods sold
3,19 մլն
3,30 մլն
3,52 մլն
3,94 մլն
Cost of revenue
3,19 մլն
3,30 մլն
3,52 մլն
3,94 մլն
Research and development expenses
3,75 մլն
5,69 մլն
5,63 մլն
5,08 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19,28 մլն
19,03 մլն
18,90 մլն
19,54 մլն
Operating expense
23,03 մլն
24,72 մլն
24,53 մլն
24,62 մլն
Total operating expenses
26,22 մլն
28,02 մլն
28,05 մլն
28,56 մլն
Operating income
-9,15 մլն
-10,41 մլն
-8,80 մլն
-6,86 մլն
Other non operating income
49,00 հզր
737,00 հզր
-95,00 հզր
-12,00 հզր
EBT including unusual items
-13,17 մլն
-11,64 մլն
-10,62 մլն
-7,63 մլն
EBT excluding unusual items
-12,27 մլն
-11,04 մլն
-10,32 մլն
-7,83 մլն
Income tax expense
15,00 հզր
-17,00 հզր
-11,00 հզր
33,00 հզր
Effective tax rate
-0,11%
0,15%
0,10%
-0,43%
Other operating expenses
-
-
-
-
Net income
-13,19 մլն
-11,62 մլն
-10,61 մլն
-7,66 մլն
Net profit margin
-77,29%
-65,97%
-55,12%
-35,31%
Earnings per share
-
-
-
-
Interest and investment income
300,00 հզր
200,00 հզր
-
500,00 հզր
Interest expense
-3,47 մլն
-1,55 մլն
-1,42 մլն
-1,46 մլն
Net interest expenses
-3,17 մլն
-1,35 մլն
-1,42 մլն
-963,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
-8,58 մլն
-9,76 մլն
-8,18 մլն
-6,25 մլն
Gain or loss from assets sale
252,00 հզր
5,00 հզր
55,00 հզր
188,00 հզր
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps